Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-24
2007-07-24
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263220, C514S263230, C514S263310, C514S263340, C514S263350, C514S263360, C544S267000, C544S244000, C544S268000, C544S269000, C544S270000, C544S271000, C544S272000, C544S273000
Reexamination Certificate
active
10861677
ABSTRACT:
The present invention provides novel adenosine receptor antagonists, more particularly, A1adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1adenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel A1adenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating A1adenosine receptor related disorders comprising administering an A1adenosine receptor antagonist of formula (I) are also disclosed. The novel A1adenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods.wherein R3is Alk14ArR16, and wherein Alk14is C1-8straight or branched alkylene or alkenylene.
REFERENCES:
patent: 2840559 (1958-06-01), Krantz et al.
patent: 2887486 (1959-05-01), Leake et al.
patent: 3031451 (1962-04-01), Schlesinger et al.
patent: 3309271 (1967-03-01), Georges et al.
patent: 3317533 (1967-05-01), De Ridder
patent: 3961060 (1976-06-01), Fuxe
patent: 4092417 (1978-05-01), Credner et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4378359 (1983-03-01), Chiodoni et al.
patent: 4548818 (1985-10-01), Kjellin et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4622324 (1986-11-01), Klessing et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4772607 (1988-09-01), Badger et al.
patent: 4868186 (1989-09-01), Franzone et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5032593 (1991-07-01), Rzeszotarski et al.
patent: 5066655 (1991-11-01), Olsson
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5208240 (1993-05-01), Peet et al.
patent: 5248770 (1993-09-01), Jacobson et al.
patent: 5256650 (1993-10-01), Peet et al.
patent: 5290782 (1994-03-01), Suzuki et al.
patent: 5296463 (1994-03-01), Lee et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5314890 (1994-05-01), Agostini et al.
patent: 5340813 (1994-08-01), Klein et al.
patent: 5395836 (1995-03-01), Shimada et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5447933 (1995-09-01), Suzuki et al.
patent: 5504090 (1996-04-01), Neely
patent: 5532368 (1996-07-01), Kufner-Muhl et al.
patent: 5543415 (1996-08-01), Suzuki et al.
patent: 5545627 (1996-08-01), Jacobson et al.
patent: 5714494 (1998-02-01), Connell et al.
patent: 5719279 (1998-02-01), Kufner-Muhl
patent: 5733916 (1998-03-01), Neely
patent: 5739331 (1998-04-01), Thyrion et al.
patent: 5786360 (1998-07-01), Neely
patent: 5932557 (1999-08-01), Mustafa et al.
patent: 6001842 (1999-12-01), Neely
patent: 6117445 (2000-09-01), Neely
patent: 6187780 (2001-02-01), Blech et al.
patent: 6919337 (2005-07-01), Bhalay et al.
patent: 7135475 (2006-11-01), Dunten et al.
patent: 2002/0058667 (2002-05-01), Castelhano et al.
patent: 2002/0058669 (2002-05-01), Van Helden et al.
patent: 2002/0082269 (2002-06-01), Neely
patent: 2002/0111333 (2002-08-01), Lin et al.
patent: 2003/0114469 (2003-06-01), Cohen
patent: 2003/0212082 (2003-11-01), Linden et al.
patent: 2004/0014766 (2004-01-01), Dunten et al.
patent: 2004/0110774 (2004-06-01), Wilson
patent: 2004/0259889 (2004-12-01), Smits et al.
patent: 2005/0119258 (2005-06-01), Wilson et al.
patent: 2005/0222179 (2005-10-01), Ensinger et al.
patent: 2005/0261316 (2005-11-01), Kalla et al.
patent: 2006/0135467 (2006-06-01), Zablocki et al.
patent: 2006/0205745 (2006-09-01), Kuroda et al.
patent: 636 828 (1964-03-01), None
patent: 1 245 383 (1967-07-01), None
patent: 26 59 241 (1978-07-01), None
patent: 0 501 379 (1992-09-01), None
patent: 0 503 563 (1992-09-01), None
patent: 0 764 647 (1997-03-01), None
patent: 2 483 922 (1981-11-01), None
patent: 947495 (1964-01-01), None
patent: 9216883 (1997-08-01), None
patent: WO 98/03507 (1998-01-01), None
patent: WO 99/67239 (1999-12-01), None
patent: WO 01/34610 (2001-05-01), None
patent: WO 03/028730 (2003-04-01), None
patent: WO 03/028730 (2003-10-01), None
patent: WO 2004/074247 (2004-09-01), None
patent: WO 2004/110379 (2004-12-01), None
patent: WO 2004110379 (2004-12-01), None
Abbracchio, M.P. and F. Cattabeni, “Selective Activity of Bamifylline on Adenosine A1-Receptors in Rat Brain,”Pharmacological Research Communications, 1987, pp. 537-545, vol. 19(8).
Beauglehole, A.R., et al., “Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A1-Adenosine Receptor,”J. Med. Chem., 2000, pp. 4973-4980, vol. 43.
Beauglehole, A.R., et al., “New Irreversible Adenosine A1Antagonists Based on FSCPX,”Bioorganic and Medicinal Chemist Letters, 2002, pp. 3179-3182, vol. 12.
Belardinelli, L., et al., “1,3-Dipropyl-8-[2-(5,6-Epoxy)Norbomyl]Xanthine, a Potent Specific and Selective A1Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT1MF-2 Cells,”The Journal of Pharmacology and Experimental Therapeutics, 1995, pp. 1167-1176, vol. 276 (2).
Belliardo, F. and C. Lucarelli, “Micro-Scale Liquid Chromatographic Method for the Determination of Bamifylline and its Major Metabolite in Human Plasma,”Journal of Chromatography, 1990, pp. 305-309, vol. 535.
Carlucci, G., et al., “Determination of Bamifylline Hydrochloride Impurities in Bulk Material and Pharmaceutical Forms Using Liquid Chromatography with Ultraviolet Detection,”Journal of Pharmaceutical&Biomedical Analysis, 1990, pp. 1067-1069, vol. 8.
Foley, L.H. et al., “Modified 3-Alkyl-1,8-dibenzylxanthines as GTP-Competitive Inhibitors of Phosphoenolpyruvate Carboxykinase,”Bioorganic&Medicinal Chemistry Letters, 2003, pp. 3607-3610, vol. 13.
Hess, S., “Recent Advances in Adenosine Receptor Antagonist Research,”Expert Opin. Ther. Patents, 2001, pp. 1533-1561, vol. 11 (10).
Jacobson, K.A., et al., “A Functionalized Congener Approach to Adenosine Receptor Antagonists: Amino Acid Conjugates of 1,3-Dipropylxanthine,”Molecular Pharmacology, 1985, pp. 126-133, vol. 29.
Jacobson, K.A., et al., “Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential,”Journal of Medicinal Chemistry, Feb. 1992, pp. 407-422, vol. 35(3).
Jacobson, K.A., et al., “Electrophilic Derivatives of Purines as Irreversible Inhibitors of A1Adenosine Receptors,”Journal of Medicinal Chemistry, 1989, pp. 1043-1051, vol. 32.
Jacobson, K.A., et al., “Molecular Probes for Extracellular Adenosine Receptors,”Biochemical Pharmacology, 1987, pp. 1697-1707, vol. 36(10).
Kuroda, S., et al., “Design, Synthesis and Biological Evaluation of a Novel Series of Potent, Orally Active Adenosine A1Receptor Antagonists with High Blood-Brain Barrier Permeability,”Chem. Pharm. Bull., 2001, pp. 988-998, vol. 49.
Müeller, C.E., et al., “7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1Selective Adenosine Receptor Antagonists,” 1990, pp. 2822-2828, vol. 33(10).
Neely, C.F., et al., “A1Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart,”AHA-Circulation, Nov. 1996, pp. 1-5, 94(9).
Nicot, G. and G. Lachatre, “High-Performance Liquid Chromatographic Method for the Determination of Bamifylline and its Three Metabolites in Human Plasma,”Journal of Chromatography, 1983, pp. 239-249, vol. 277.
Novellino, E., et al., “Design, Synthesis and Biological Evaluation of NovelN-Alkyl- andN-Acyl-(7-subsituted-2-2phenylimidazo[1,2-a] [1,3,5] triazin-4-yl] amines (ITAs) as Novel A1Adenosine Receptor Antagonists,”J. Med. Chem., 2002, pp. 5030-5036, vol. 45.
Patel, A. et al., “I-BW-A844U, an Antagonist Radioligand with High Affinity and Selectivity for Adenosine A1Receptors, and125I-Azido-BW-A844U, a Photoaffinity Label,”Molecular Pharmacology, 1988, pp. 585-591, vol. 33.
Poulsen, S-A and R.J. Quinn, “Adenosine Receptors:
Partridge John J.
Wilson Constance N.
Alston & Bird LLP
Berch Mark L.
Endacea, Inc.
LandOfFree
A1 adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A1 adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A1 adenosine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750703